Oral Yupingfeng combined with inhaled salmeterol xinafoate/fluticasone propionate for cough variant asthma

Abstract

Objective To detect the clinical effects of Yupingfeng granules combined with Seretide on the patients with cough variant asthma (CVA). Methods A total of 96 CVA patients were enrolled in this study. Patients were randomly divided into the Seretide control group (n=48) and Yupingfeng granules combined with Seretide treatment group (n=48). The control group was given Seretide treatment, and the treatment group was treated with Yupingfeng granules and Seretide. The eosinophil (EOS) proportion was calculated by wright staining in induced sputum. The IL-17 and IL-6 expression was detected by ELISA analyses. The rate of clinic effects and adverse reaction was compared. Results After treatment, EOS proportion (9.63% ± 2.24% vs. 14.26% ± 3.27%, t=3.415), IL-17 (18.71 ± 4.32 ng/ml vs. 27.42 ± 6.41 ng/ml, t=3.146), and IL-6 (20.35 ± 5.23 ng/ml vs. 31.47 ± 7.36 ng/ml, t=3.517) expression in the treatment group was significantly lower than those in the control group (P<0.05 ). The cough relief time (7.42 ± 2.13 d vs. 6.07 ± 1.82 d, t=2.576) and disappearance time (14.54 ± 2.78 d vs. 10.46 ± 2.31 d, t=2.712) in the treatment group was significantly lower than those in the control group (P<0.05). The rate of clinic effects (91.7% vs. 79.2%, χ2=2.426) in the treatment group was siginificantly better than that in the control group (P=0.042). The recurrent rate (6.8% vs. 21.1%, χ2=3.316) in the treatment group was siginificantly lower than that in the control group (P=0.024). Conclusions The Yupingfeng granules combined with Seretide could reduce EOS proportion, IL-17 and IL-6 expression to inhibit inflammatory reaction on the patients with CVA. Key words: Cough variant asthma; Eosinophil; Interleukin-17; Interleukin-6; Yupingfeng granules